Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats

Experimental Physiology

Volumn 95, Issue 1, 2010, Pages 51-55

  Yemane, Henok ^a   Busauskas, Marius ^a   Burris, Sarah K ^a   Knuepfer, Mark M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIL; BOSENTAN; DEOXYCORTICOSTERONE ACETATE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; NEUROHORMONE; SODIUM; VASOPRESSIN; VASOPRESSIN ANTAGONIST;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; CONFERENCE PAPER; DIET; HYPERALDOSTERONISM; HYPEROSMOLALITY; HYPERTENSION; HYPERVOLEMIA; KIDNEY NERVE; NEUROTRANSMISSION; NONHUMAN; SALT INTAKE; SODIUM BLOOD LEVEL; SYMPATHETIC NERVE; VASOPRESSIN RELEASE;

EID: 74049107807     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.046334     Document Type: Conference Paper

References (41)

1. Abrams JM Osborn JW (2008). Osmoregulatory function in health disease: a role for benzamil-sensitive proteins of the central nervous system in the pathogenesis of salt-dependent hypertension. Clin Exp Pharmacol Physiol 35, 687 694.
2. Bird JE, Moreland S, Waldron TL Powell JR (1995). Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 25, 1191 1195.
3. Bouvier M de Champlain J (1986). Increased basal and reactive plasma norephinephrine and epinephrine levels in awake DOCA-salt hypertensive rats. J Auton Nerv Syst 15, 191 195.
4. Brody MJ Johnson AK (1980). Role of the anteroventral third ventricle region in fluid and electrolyte balance, arterial pressure regulation, and hypertension. Front Neuroendocrinol 6, 249 292.
5. Brooks VL, Freeman KL Qi Y (2006). Time course of synergistic interaction between DOCA and salt on blood pressure: roles of vasopressin and hepatic osmoreceptors. Am J Physiol Regul Integr Comp Physiol 291, R1825 R1834.
6. Bruner CA, Mangiapane ML, Fink GD Webb RC (1988). Area postrema ablation and vascular reactivity in deoxycorticosterone-salt treated rats. Hypertension 11, 668 673.
7. Crofton JT, Share L, Shade RE, Lee-Kwon WJ, Manning M Sawyer WH (1979). The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat. Hypertension 1, 31 38.
8. Dzielak DJ Norman RA (1985). Renal nerves are not necessary for onset or maintenance of DOC-salt hypertension in rats. Am J Physiol Heart Circ Physiol 249, H945 H949.
9. Fink GD, Johnson RJ Galligan JJ (2000). Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension. Hypertension 35, 464 469.
10. Guild S-J, Barrett CJ, McBryde FD, Van Vliet BN Malpas SC (2008). Sampling of cardiovascular data; how often and how much? Am J Physiol Regul Integr Comp Physiol 295, R510 R515.
11. Guyton AC, Coleman TG, Cowley AW, Scheel KW, Manning RD Norman RA (1972). Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52, 584 594.
12. Haack D, Möhring J, Möhring B, Petri M Hackenthal E (1977). Comparative study on development of corticosterone and DOCA hypertension in rats. Am J Physiol Renal Physiol 233, F403 F411.
13. Jacob F, Clark LA, Guzman PA Osborn JW (2005). Role of renal nerves in development of hypertension in DOCA-salt model in rats: a telemetric approach. Am J Physiol Heart Circ Physiol 289, H1519 H1529.
14. Katholi RE, Naftilan AJ Oparil S (1980). Importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat. Hypertension 2, 266 273.
15. Knuepfer MM, Akeyson EW Schramm LP (1988). Spinal projections of renal afferent nerves in the rat. Brain Res 446, 17 25.
16. Kopp UC, Cicha MZ Smith LA (2003). Arterial pressure increases in afferent renal denervated rats on high-sodium diet. Hypertension 42, 968 973.
17. Kopp UC, Jones SY DiBona GF (2008). Afferent renal denervation impairs baroreflex control of efferent renal sympathetic nerve activity. Am J Physiol Regul Integr Comp Physiol 295, R1882 R1890.
18. Lariviere R, Day R Schiffrin EL (1993). Increased expression of endothenlin-1 gene in blood vessel of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 21, 916 920. (Pubitemid 23166939)
19. Lerman LO, Chade AR, Sica V Napoli C (2005). Animal models of hypertension: an overview. J Lab Clin Med 146, 160 173.
20. A-NADPH oxidase pathway in low-renin hypertension. Circulation 107, 1053 1058.
21. Li L, Galligan JJ, Fink GD Chen AF (2003b). Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension. Hypertension 41, 663 668.
22. Matsuguchi H Schmid PG (1982). Acute interaction of vasopressin and neurogenic mechanisms in DOC-salt hypertension. Am J Physiol Heart Circ Physiol 242, H27 H43.
23. Miki K, Kosho A Hayashida Y (2002). Method for continuous measurements of renal sympathetic nerve activity and cardiovascular function during exercise in rats. Exp Physiol 87, 33 39.
24. Mimura Y, Ogura T, Yamauchi T, Otsuka F, Oishi T, Harada K, Hashimoto M Ota Z (1995). Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats. Acta Med Okayama 49, 187 194.
25. Möhring J Möhring B (1972). Reevaluation of DOCA escape phenomenon. Am J Physiol 223, 1237 1245.
26. Möhring J, Möhring B, Petri M Haack D (1977). Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension. Am J Physiol Renal Physiol 232, F260 F269.
27. O'Donaughy TL Brooks V (2006). Deoxycorticosterone acetate-salt rats: hypertension and sympathoexcitation driven by increased NaCl levels. Hypertension 47, 680 685.
28. Okada H, Suzuki H, Kanno Y Saruta T (1995). Effect of nonpeptide vasopressin receptor antagonists on developing, and established DOCA-salt hypertension in rats. Hypertension 17, 469 483.
29. Reid JK, Zivin JA Kopin I (1975). Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res 37, 569 579.
30. Schenk J McNeill JH (1992). The pathogenesis of DOCA-salt hypertension. J Pharmacol Toxicol Methods 27, 161 170.
31. Supowit SC, Zhao H, Hallman DM DiPette DJ (1997). Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension 29, 945 950. (Pubitemid 27152463)
32. Takeda K Bunag RD (1980). Augmented sympathetic nerve activity and pressor responsiveness in DOCA hypertensive rats. Hypertension 2, 97 101. (Pubitemid 10061192)
33. Titze J, Bauer K, Schafflhuber M, Dietsch P, Lang R, Schwind KH, Luft FC, Eckardt K Hilgers KF (2005). Internal sodium balance in DOCA-salt rats: a body composition study. Am J Physiol Renal Physiol 289, F793 F802.
34. Van Huysse JW (2007). Endogenous brain Na pumps, brain ouabain-like substance and the α2 isoform in salt-dependent hypertension. Pathophysiology 14, 213 220.
35. Villamil MF, Amorena C, Ponce J, Muller A Taquini AC (1981). Acute saline expansion lowers blood pressure of early DOCA-salt hypertensive rats. Pflugers Arch 390, 260 261.
36. Villamil MF, Amorena C, Ponce-Hornos J, Muller A Taquini AC (1982). Role of extracellular volume expansion in the development of DOC-salt hypertension in the rat. Hypertension 4, 620 624.
37. Yamamoto J, Yamane Y, Umeda Y, Yoshioka T, Nakai M Ikeda M (1984). Cardiovascular hemodynamics and vasopressin blockade in DOCA-salt hypertensive rats. Hypertension 6, 397 407.
38. Yu M, Gopalakrishnan V McNeill JR (1998). Hemodynamic effects of a selective endothelin-a receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. J Cardiovasc Pharmacol 31, S262 S264.
39. Yu M, Gopalakrishnan V McNeill JR (2001a). Role of endothelin and vasopressin in DOCA-salt hypertension. Br J Pharmacol 132, 1447 1454.
40. Yu M, Gopalakrishnan V, Wilson TW McNeill JR (2001b). Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension. Am J Physiol Heart Circ Physiol 281, H2511 H2517.
41. Zicha J, Kunes J, Lebl M, Pohlova I, Slaninova J Jelinek J (1989). Antidiuretic and pressor actions of vasopressin in age-dependent DOCA-salt hypertension. Am J Physiol Regul Integr Comp Physiol 256, R138 R145.